At the American Chemical Society national conference last weekend, Rensselaer Polytechnic researcher Dr. Robert Linhart announced that his team may have built the first fully synthetic heparin. Whether or not you believe that the possibility of another contamination crisis of natural raw heparin exists, the potential for a heparin supply...
Agents seized $24 million in unapproved guaifenesin and time-released treatments from KV Pharmaceuticals. In case you missed it here's the news that appeared today. The company is disposing of these supplies. Watch local news coverage here.
The story, click here for our version (one of thousands circulating) ----which explains the Valentine's Day inspections at Ranbaxy's U.S. headquarters last year--- has been generating a lot of buzz this week. Also mentioned in the allegations is Parexel Consulting, the consulting arm of contract manufacturer Parexel, which had a...
Ever see the old Abbott and Costello "who's on first" baseball routine? "I don't know" was on third base. Pharma is not the only industry that suffers from less-than-perfect supply chain risk management, as Juran Institute CEO Joe De Feo pointed out in a recent audio interview.
We all know that physicians must distance themselves from patients to keep from becoming too emotionally involved in each case. Perhaps this applies to drug development and manufacturing as well, and industry profesionals may risk viewing adverse patient reactions as a mere statistic.
Clinical trials may have uncovered a possible link between inhaled insulin and lung cancer. In testing its blockbuster manque Exubera, Pfizer said six of the 4,740 Exubera-treated patients versus one of the 4,292 patients not treated with Exubera developed lung cancer.
Forget about championing one side or another. The politically charged "generics vs. namebrand drug" debate offers an opportunity to study the impacts of process and ingredient variability on drug manufacturing and on clinical effects in patients. (For material to analyze, click here).
Have been away from the epicenter of political corruption for a while. New York is quite a bit tamer on that score than Chicago. Not so its tabloid headline writing (especially at the New York Post), which is as brilliant as it is uncivilized.
Am starting to feel like the witch in "The Wiz" -- "Don't nobody bring me no bad news." A quick look at some headlines brought yet another story of blockbuster-challenged pharma ethics, this time involving Germany's Bayer AG.